N@N

Illumina Announces MiSeqa" Personal Sequencing System

^{Published on 2011-01-11 16:26:09 - Market Wire}
 

SAN DIEGO--([ BUSINESS WIRE ])--Illumina, Inc. (NASDAQ:ILMN) today announced MiSeqa", a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Leveraging the companya™s TruSeqa" sequencing chemistry, the systema™s revolutionary workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day. Expected to be priced under $125,000 with individual run prices ranging from $400-$750, MiSeq will be the most affordable next-generation sequencing (NGS) platform available.

"MiSeq takes advantage of recent advances in our sequencing chemistry, including significantly faster cycle times and simplified sample preparation, to deliver next-generation sequencing to individual researchers, especially those who currently use capillary electrophoresis (CE) sequencers"

aMiSeq takes advantage of recent advances in our sequencing chemistry, including significantly faster cycle times and simplified sample preparation, to deliver next-generation sequencing to individual researchers, especially those who currently use capillary electrophoresis (CE) sequencers,a said Jay Flatley, President and CEO of Illumina. aUsers will also benefit greatly from MiSeqa™s compact footprint of approximately 2 feet square, intuitive user interface, simple workflow, and low capital and run price. The platform will enable applications such as amplicon sequencing, clone checking, small genome sequencing, ChIP-Seq, and RNA-Seq, all with a single, integrated instrument and at a fraction of current costs and time.a

Using Illuminaa™s proven TruSeq chemistry, MiSeq provides users the flexibility to optimize run conditions to suit their particular applications. Like all other Illumina sequencing platforms, MiSeq performs both single and paired-end runs with read lengths of up to 2 x 150 base pairs. The ability to support paired-end reads is critical for a broad range of applications including amplicon sequencing, sequencing of complex genome regions, and efficient mapping. The platform also leverages a new proprietary protocol for efficient and cost-effective targeting of 10s to 100s of amplicons, allowing CE users to complete their projects in a fraction of the time at significant cost savings. To accommodate space limitations often encountered in smaller laboratories, cluster amplification has been integrated with the 2 feet square platform. This eliminates the need for additional instruments, which are often necessary to operate other NGS platforms, especially those that rely on emulsion PCR (ePCR) for sample amplification.

Illumina expects to take initial orders for the MiSeq platform starting in April 2011 and anticipates shipping the first commercial units of MiSeq in summer 2011. For more information about the MiSeq personal sequencing system, please visit [ www.illumina.com/miseq ].

About Illumina

Illumina ([ http://www.illumina.com ]) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected pricing and order and shipping dates for the MiSeq personal sequencing system. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.